DNA-PKcs阻害剤Peposertibの選択的放射線感受性増強効果による患者由来メラノーマ脳転移異種移植モデルの差次的分布に関する補足図2

Jiら（Wed,）がこの問題を研究した。

www.synapsesocial.com/papers/68e5778bb6db6435875173ee — DOI: https://doi.org/10.1158/1535-7163.27102352.v1

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Supplementary Figure 2 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts· 2024
2. Supplementary Figure 2 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts· 2024
3. Supplementary Figure 2 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts· 2024
4. Supplementary Figure 1 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts· 2024
5. Supplementary Figure 1 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts· 2024